Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing.

ABSTRACT:

Background

BCMA CAR-T is highly effective for relapsed/refractory multiple myeloma(R/R-MM) and significantly improves the survival of patients. However, the short remission time and high relapse rate of MM patients treated with BCMA CAR-T remain bottlenecks that limit long-term survival. The immune microenvironment of the bone marrow (BM) in R/R-MM may be responsible for this. The present study aims to present an in-depth analysis of resistant mechanisms and to explore potential novel therapeutic targets for relapse of BCMA CAR-T treatment via single-cell RNA sequencing (scRNA-seq) of BM plasma cells and immune cells.

Methods

This study used 10X Genomic scRNA-seq to identify cell populations in R/R-MM CD45⁺ BM cells before BCMA CAR-T treatment and relapse after BC

SUBMITTER: Li W 

PROVIDER: S-EPMC10165782 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature